Abstract: A method for treatment of irritation or damage to corneal or conjunctival epithelial cells, particularly for irritation or damage to corneal or conjunctival epithelial cells due to severe Sjögren's syndrome, comprising applying topically to an affected eye an aqueous solution of glycerol characterized by a glycerol concentration of >1% (w/v), most preferably 2.5% (w/v). The method is effective even in the case of very low tear formation, and its effectiveness cannot be explained by the known humectant effect of glycerol.

Abstract: A method for treatment of irritation or damage to conical or conjunctival epithelial cells, particularly for irritation or damage to corneal or conjunctival epithelial cells due to severe Sjögren's syndrome, comprising applying topically to an affected eye an aqueous solution of glycerol characterized by a glycerol concentration of >1% (w/v), most preferably 2.5% (w/v). The method is effective even in the case of very low tear formation, and its effectiveness cannot be explained by the known humectant effect of glycerol.

Abstract: A method for treatment of irritation or damage to conical or conjunctival epithelial cells, particularly for irritation or damage to corneal or conjunctival epithelial cells due to severe Sjögren's syndrome, by applying topically to an affected eye an aqueous solution of glycerol characterized by a glycerol concentration of >1% (w/v), most preferably 2.5% (w/v). The method is effective even in the case of very low tear formation, and its effectiveness cannot be explained by the known humectant effect of glycerol.

Abstract: The present invention provides a method of treatment of irritation of skin or mucous cells. The method comprises applying topically a composition comprising a combination of: xylitol, myonisotiol or mannitol or any combination of these; glycerol and/or urea; water; in the absence of any oil in water or wax in water emulsion.

Abstract: A method for treatment of irritation or damage to conical or conjunctival epithelial cells, particularly for irritation or damage to corneal or conjunctival epithelial cells due to severe Sjögren's syndrome, by applying topically to an affected eye an aqueous solution of glycerol characterized by a glycerol concentration of >1% (w/v), most preferably 2.5% (w/v). The method is effective even in the case of very low tear formation, and its effectiveness cannot be explained by the known humectant effect of glycerol.

Abstract: A topical pharmaceutical or cosmetic composition for treatment of irritation of mucous cells such as mucosal cells of the eye, nose, and vagina is disclosed. The composition comprises an aqueous solution of at least one polyol selected from the group consisting of xylitol, myoinositol and mannitol and at least one substance selected from the group consisting of glycerol and urea. The composition contains less than 0.01% inorganic salt and is free of any oil-in-water or wax-in-water emulsion. In particularly preferred embodiments, the composition comprises an aqueous solution containing 1.5-5% (w/v) xylitol and 0.9-2.0% (w/v) glycerol.

Abstract: A topical pharmaceutical or composition for prevention and treatment of irritation to skin cells. The composition comprises an aqueous solution of xylitol and glycerol. In a preferred embodiment, the composition comprises 5% (w/w) xylitol, 5% (w/w) glycerol, a viscosity-enhancing agent, base to bring to the pH to 4.9, and optionally, a pharmaceutically active agent.

Abstract: The present invention provides a method of treatment of irritation of skin or mucous cells. The method comprises applying topically a composition comprising a combination of: xylitol, myonisotiol or mannitol or any combination of these; glycerol and/or urea; water; in the absence of any oil in water or wax in water emulsion.

Abstract: A topical pharmaceutical or cosmetic composition for treatment of irritation of mucous cells such as mucosal cells of the eye, nose, and vagina is disclosed. The composition comprises an aqueous solution of at least one polyol selected from the group consisting of xylitol, myoinositol and mannitol and at least one substance selected from the group consisting of glycerol and urea. The composition contains less than 0.01% inorganic salt and is free of any oil-in-water or wax-in-water emulsion. In particularly preferred embodiments, the composition comprises an aqueous solution containing 1.5-5% (w/v) xylitol and 0.9-2.0% (w/v) glycerol.

Abstract: A composition for delivering cholecalciferol to skin and/or mucous membranes via topical application. The composition comprises xylitol and cholecalciferol in emulsion. Optionally, the composition may include additional components such as glycerol, polyethylene glycol, propylene glycol, pharmaceutical agents, stabilizers, acids, bases, buffers, antioxidants, emulsifiers, suspending agents, and preservatives. Methods of preparation of the composition and of using it as a topical treatment for delivery of cholecalciferol to the skin and/or mucous membranes are also disclosed.

Abstract: An ophthalmic preparation and method, usable to treat conjunctivochalasis. The ophthalmic preparation comprises an aqueous solution of glycerol. The preparation may also include additional components including high molecular weight polymers for viscosity control and pharmacologically active substances. The method includes administering an ophthalmic preparation including an aqueous solution of glycerol to a patient.

Abstract: An ophthalmic preparation and method, usable to treat conjunctivochalasis. The ophthalmic preparation comprises an aqueous solution of glycerol. The preparation may also include additional components including high molecular weight polymers for viscosity control and pharmacologically active substances. The method includes administering an ophthalmic preparation including an aqueous solution of glycerol to a patient.

Abstract: The present invention provides new topical pharmaceutical or cosmetic compositions for the prevention and treatment of irritation of mucous cells, or skin cells, comprising a combination of: xylitol, myoinositol or mannitol or any combination of these; glycerol and/or urea; water; in the absence of any oil in water or wax in water emulsion.

Abstract: The present invention concerns Topical skin preparations for the use in the prevention of atrophy and aging of the skin, comprising a testosterone ester with an esterifying acid having between six to eleven carbon atoms.

Abstract: There are provided pharmaceutical compositions for intranasal application for the alleviation of nasal discomforts, like "dry nose syndrome" and for the treatment of a variety of diseases. These are based on the combination of an isotonic humectant solution and a high molecular weight polymer which provides the required viscosity. Preferred compositions have a non-Newtonian viscosity profile. The composition can contain one or more pharmaceutically active ingredient.

Abstract: Isotonic humectant eyedrops which have pronounced non-Newtonian rheological properties, simulating the rheological behavior of human tears. The eyedrops are of value in the treatment of various abnormal states of the eye such as dry eye syndrome. They can also serve as carrier for a variety of pharmaceutically active ingredients. Essential components are in combination water, an anionic polymer having a M.W. in the 500,000 to about 4,000,000 range at a concentration so that the viscosity measured at a 1 sec.sup.-1 shear rate does not exceed about 150 cp. and a low molecular weight (of 500 or less M.W.) humectant polyol at a concentration of about isotonicity or slightly above. The solution must contain less than about 1.5 mM salt calculated as sodium chloride, not including the salts of the anionic polymeric viscosity enhancer, as higher concentrations destroy the non-Newtonian rheological properties. A process for treating dry eye syndrome by application of such eyedrops.

Abstract: Cosmetic and dermatological compositions containing 1.alpha.-hydroxycholeciferol and a suitable carrier useful in topical treatment of skin disorders and methods employing same are disclosed. Compositions containing 1.alpha.,25-dihydroxycholecalciferol and a suitable carrier and methods employing same are also disclosed for dermatological and cosmetic uses. Various formulations of the compositions including creams, lotions, ointments and sprays are disclosed for use in accordance with this invention. The compositions and formulations may contain additional active ingredients.

Abstract: The present invention relates to pharmaceutical and veterinary compositions for use as sex stimulants for mammals which comprise an active ingredient phenylethylamine substituted in the ortho or in the meta position by a methoxy group, a methylthio group, by a chlorine atom or by a bromine atom, as well as salts and complexes of these compounds. The invention further relates to the ortho- and meta- methoxyphenylethylamine and methylthiophenylethylamine compounds and to their salts and complexes as novel compounds.

Abstract: The present invention relates to novel compounds of the general formula ##STR1## wherein R.sup.1 is --H or --CO--alk, wherein alk is lower alkyl of 1 to 5 carbon atoms; R.sup.2 is 1,1-dimethylheptyl or 1,2-dimethylheptyl, Q is --CH.sub.3 when A------B is a single bond, and Q is --CH.sub.2 OR.sup.4 when A------B is a double bond, and R.sup.4 is --H or --CO--alk where alk is lower alkyl of 1 to inclusive 5 carbon atoms.The invention relates both to the isomeric mixtures and to the individual isomers of the above compounds. Furthermore the invention relates to pharmaceutical compositions containing a compound defined above as active ingredient. The pharmaceutical compositions are of value as central nervous system depressants, as sedatives, as tranquilizers, as anticonvulsant agents, as effective agents against migraine, for the treatment of glaucoma, as antidiarrheal agents and as antiinflammatory agents.

Abstract: Cosmetic and dermatological compositions containing 1.alpha.-hydroxycholeciferol and a suitable carrier useful in topical treatment of skin disorders and methods employing same are disclosed. Compositions containing 1.alpha.,25-dihydroxycholecalciferol and a suitable carrier and methods employing same are also disclosed for dermatological and cosmetic uses. Various formulations of the compositions including creams, lotions, ointments and sprays are disclosed for use in accordance with this invention. The compositions and formulations may contain additional active ingredients.